Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
Not wanting to be caught flat-footed upon potential approval, Revive is “In discussions with its manufacturing partner to secure commercial supply of at least 5 billion Bucillamine tablets to potentially treat at least 50 million people globally for 2022.
Revive CEO Michael Frank, stated “We recognize the market opportunity for Bucillamine and we are in discussions with our manufacturing partners to ensure that billions of Bucillamine tablets can be made available in 2022 to support our future commercialization partners and the millions of people globally.”
The Company is continuing discussions with reputable international pharmaceutical companies seeking to obtain commercial rights to Bucillamine as a treatment for COVID-19 in various countries in Europe, India and Asia. In light of these discussions, Revive is pursuing a commercialization plan that would leverage the clinical results from the U.S. Phase 3 study to allow for drug approvals globally.
Michael Frank, CEO of the Company commented, “As we move forward in our Phase 3 study in COVID-19 with the aim to seek EUA approval from the FDA for Bucillamine in the treatment of mild to moderate COVID-19, we are also cognizant of the rapidly changing landscape of COVID-19 specifically with the Delta variant becoming widespread.
The incorporation of adding viral load testing to patients in the Study, along with our support in the research of the potential utility of thiol-based drugs, like Bucillamine, in the Delta variant of COVID-19, shows our confidence in Bucillamine’s potential as a safe and effective oral treatment for mild to moderate COVID-19. We recognize the market opportunity for Bucillamine and we are in discussions with our manufacturing partners to ensure that billions of Bucillamine tablets can be made available in 2022 to support our future commercialization partners and the millions of people globally.”
Read full press release here. Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial
The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.
Client, see report for full disclosure and disclaimer details.
#RVVTF $RVVTF, #RVV, $RVV
